The 16th European LeukemiaNet Symposium will take place on 12 February 2019 in Mannheim, Germany.
HARMONY partners will present updates about current projects. Stay tuned for more information.
Practical Information
The European LeukemiaNet (ELN) is a publicly funded research network of excellence. Goal is cure of leukemia by integration of European leukemia research and excellence. ELN is a HARMONY Partner. 220 Participating Centers in 40 Countries (1000 Researchers and Associates) are cooperating in the European Leukemia Net. The objective is to integrate the 108 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, CMPD), their 105 interdisciplinary partners (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a cooperative network for advancements in leukemia related research and health care.
Prof. Rüdiger Hehlmann, Founder and Chair of the European LeukemiaNet (ELN) and founder and Chair of the ELN Foundation published an article in Cancer 2017 about advancing a field by building consortia.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
